Your browser doesn't support javascript.
A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce.
Carter, Nikki; Clausen, Maryam; Halpin, Rebecca A; Blackmore, Colin; Cai, Kang; Delpuech, Oona; Kohlmann, Alexander; Magnusson, Otto; March, Ruth; O'Neill, Daniel; Prakash, Kasthuri; Sherwood, James; Sundin, Tabetha; Swift, Jason; Tarakameh, Azar; Wijdicks, Marilou; Wise, Daniel; Fidock, Mark.
  • Carter N; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Clausen M; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Halpin RA; Early Oncology, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Blackmore C; R&D IT, AstraZeneca, Cambridge, UK.
  • Cai K; Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Delpuech O; Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Kohlmann A; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Magnusson O; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • March R; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.
  • O'Neill D; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Prakash K; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Sherwood J; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Sundin T; Global Medical Affairs, Oncology Business Unit, AstraZeneca, Gaithersburg, MD, USA.
  • Swift J; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Tarakameh A; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Wijdicks M; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Wise D; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Fidock M; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK. mark.fidock@astrazeneca.com.
Sci Rep ; 11(1): 12676, 2021 06 16.
Article in English | MEDLINE | ID: covidwho-1275954
ABSTRACT
Regular PCR testing of nasopharyngeal swabs from symptomatic individuals for SARS-CoV-2 virus has become the established method by which health services are managing the COVID-19 pandemic. Businesses such as AstraZeneca have also prioritised voluntary asymptomatic testing to keep workplaces safe and maintain supply of essential medicines to patients. We describe the development of an internal automated SARS-CoV-2 testing programme including the transformative introduction of saliva as an alternative sample type.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Saliva / Workforce / Asymptomatic Diseases / Pandemics / Real-Time Polymerase Chain Reaction / COVID-19 Nucleic Acid Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-92070-w

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Saliva / Workforce / Asymptomatic Diseases / Pandemics / Real-Time Polymerase Chain Reaction / COVID-19 Nucleic Acid Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-92070-w